Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Ligand Pharmaceuticals Incorporated < Previous 1 2 Next > Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy September 06, 2024 From Ligand Pharmaceuticals Incorporated Via Business Wire Tickers LGND Ligand to Present at H.C. Wainwright 26th Annual Global Investment Conference August 20, 2024 From Ligand Pharmaceuticals Incorporated Via Business Wire Tickers LGND Ligand Reports Second Quarter 2024 Financial Results August 06, 2024 From Ligand Pharmaceuticals Incorporated Via Business Wire Tickers LGND Ligand to Report Second Quarter 2024 Financial Results on August 6, 2024 July 23, 2024 From Ligand Pharmaceuticals Incorporated Via Business Wire Tickers LGND Ligand to Acquire APEIRON Biologics AG for $100 Million July 08, 2024 From Ligand Pharmaceuticals Incorporated Via Business Wire Tickers LGND Ligand Partner Verona Pharma Announces FDA Approval of Ohtuvayre™ (ensifentrine), First Inhaled Novel Mechanism for Maintenance Treatment of COPD in More Than 20 Years June 27, 2024 From Ligand Pharmaceuticals Incorporated Via Business Wire Tickers LGND Ligand Collaborator Merck Receives FDA Approval for CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Adults June 18, 2024 From Ligand Pharmaceuticals Incorporated Via Business Wire Tickers LGND Ligand to Participate in Upcoming Investor Conferences May 23, 2024 From Ligand Pharmaceuticals Incorporated Via Business Wire Tickers LGND Ligand Reports First Quarter 2024 Financial Results May 07, 2024 From Ligand Pharmaceuticals Incorporated Via Business Wire Tickers LGND Ligand and Agenus Enter Into $100 Million Royalty Financing Agreement May 07, 2024 From Ligand Pharmaceuticals Incorporated Via Business Wire Tickers AGEN LGND Ligand to Report First Quarter 2024 Financial Results on May 7, 2024 April 23, 2024 From Ligand Pharmaceuticals Incorporated Via Business Wire Tickers LGND Ligand Pharmaceuticals Announces New Topiramate Injection Data Presented at 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference April 08, 2024 From Ligand Pharmaceuticals Incorporated Via Business Wire Tickers LGND Ligand Pharmaceuticals Announces Launch of Pelthos Therapeutics to Accelerate Commercialization of ZELSUVMI™ April 03, 2024 From Ligand Pharmaceuticals Incorporated Via Business Wire Tickers LGND Ligand Pharmaceuticals to Present at Barclays 26th Annual Global Healthcare Conference March 05, 2024 From Ligand Pharmaceuticals Incorporated Via Business Wire Tickers LGND Ligand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) March 04, 2024 From Ligand Pharmaceuticals Incorporated Via Business Wire Tickers LGND Ligand Reports Fourth Quarter and Full Year 2023 Financial Results February 27, 2024 From Ligand Pharmaceuticals Incorporated Via Business Wire Tickers LGND Ligand Partner Eisai Receives Approval in Japan for Injection Formulation of Antiepileptic Drug Fycompa® February 22, 2024 From Ligand Pharmaceuticals Incorporated Via Business Wire Tickers LGND Ligand Pharmaceuticals Expands Senior Leadership Team with Two Key Hires February 16, 2024 From Ligand Pharmaceuticals Incorporated Via Business Wire Tickers LGND Ligand to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024 February 13, 2024 From Ligand Pharmaceuticals Incorporated Via Business Wire Tickers LGND Ligand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) February 01, 2024 From Ligand Pharmaceuticals Incorporated Via Business Wire Tickers LGND U.S. Food and Drug Administration Approves ZELSUVMI™ as a First-in-Class Medication for the Treatment of Molluscum Contagiosum January 05, 2024 From Ligand Pharmaceuticals Incorporated Via Business Wire Tickers LGND Ligand Holds Investor and Analyst Day; Provides Update on Portfolio Progress and Recent Transactions; Introduces 2024 Guidance December 12, 2023 From Ligand Pharmaceuticals Incorporated Via Business Wire Tickers LGND Ligand to Host Investor and Analyst Day on December 12, 2023 in New York City December 06, 2023 From Ligand Pharmaceuticals Incorporated Via Business Wire Tickers LGND Ligand Reports Third Quarter 2023 Financial Results November 08, 2023 From Ligand Pharmaceuticals Incorporated Via Business Wire Tickers LGND Ligand Acquires Royalty on Sanofi’s TZIELD® for $20 Million November 01, 2023 From Ligand Pharmaceuticals Incorporated Via Business Wire Tickers LGND Ligand To Report Third Quarter 2023 Financial Results On November 8 October 25, 2023 From Ligand Pharmaceuticals Incorporated Via Business Wire Tickers LGND Ligand Acquires Assets of Novan, Inc. for $12.2 Million September 27, 2023 From Ligand Pharmaceuticals Incorporated Via Business Wire Tickers LGND Ligand Appoints Martine Zimmermann to its Board of Directors September 26, 2023 From Ligand Pharmaceuticals Incorporated Via Business Wire Tickers LGND Ligand’s Partner Jazz Pharmaceuticals Receives European Commission Approval for Enrylaze® (a recombinant Erwinia asparaginase or crisantaspase) for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma September 22, 2023 From Ligand Pharmaceuticals Incorporated Via Business Wire Tickers LGND Ligand’s Partner Travere Therapeutics Announces Confirmatory Data from the Phase 3 PROTECT Study of FILSPARI® Demonstrating Long-Term Kidney Function Preservation in IgA Nephropathy; Narrowly Missing eGFR Total Slope Endpoint versus Active Control September 21, 2023 From Ligand Pharmaceuticals Incorporated Via Business Wire Tickers LGND < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.